MD4001 Drugs

short acting, proline-28--> aspartic acid on the beta chain, can't make hexamers and dimers

Medium acting Insulin, Polypeptide complexes, forms aggregates

Insulin complexed with zinc, makes hexamers

Long acting, glycine for asparagine N21 and 2 arganine acids added to the end of the beta chain, not soluble at neutral pH

Sulphonurea (K+ channel)

Sulphonurea (K+ channel)

Sulphonurea (K+ channel)

Sulphonurea (K+ channel)

K+ channel blocker with less weight gain

K+ channel blocker with less weight gain

Increases the ATP/AMP ratio within the cell, increasing AMPK which increases the cells sensitivity to insulin

PPAR receptor activator whih increases insulin sensitivity by about 30%

Glitazone

alpha glucosidase inhibitor which reduces absorption of carbohydrate

GLP-1 analogue

LAR form of exenatide

GLP-1 analogue with albumin binding and slow renal clearance

DPP-4 inhibitor

DPP-4 inhibitor not used in the USA

DPP-4 inhibitor not used in the USA

1st line Epilepsy, Inhibits sodium channels, (hypersensitivity reactions),

Old 1st line for epilepsy, GABA increase, Hair loss and foetal syndrome

epilepsyDerivative of tricyclic antidepressants, partial seizures and trigeminal neuralgia,enzyme inducing, blocks Na channels use dependent

epilepsy closely related to carbazepine, less side effects, Na+ channels, K+ channels

epilepsy Presynptic Ca, psychiactric side effects

epilepsy GABA uptake inhibitor, dizziness and confusion, partial seizures

epilepsy Blocks Na channels, anorexia, Ca2+ channels

epilepsy Use dependent block Na+ channels not absence seizures, 0 order kinetics

epilepsy Absence seizures in children

epilepsy enzyme inducing, very long half life, osteoporosis

epilepsy severe hypersensitivity- aplastic anaemia

epilepsy Inhibits GABA transaminase, bad side effects

Parkinsons, combine with DOPA decarboxylase inhibitor, involuntary writhing after 2 years,

Dopamine agonist, D1 and D2 receptors

Dopamine agonist, D1 and D2 receptors

Dopamine agonist, D1 and D2 receptors

Dopamine agonist, D2/3 selective receptors

Dopamine agonist , D2/3 selective receptors

Dopamine agonist delivered via transdermal patch

Dopamine agonist, given by injection to control on/off effect of Levodopa

MAO-B inhibitor(selective), protects dopamine from extraneural degredation,

MAO inhibitor, may retard disease progression

Dopa decarboxylase inhibitor

Dopa decarboxylase inhibitor

antiviral shown to be beneficial to PD, increased dopamine release,

Acetylcholine antagonist, ACh usually inhibits dopamine release

ACh receptor antagonist, ACh usually inhibits dopamine release

ACh receptor antagonist, ACh usually inhibits dopamine release, these drugs all have anticholinergic side effects

COMT inhibitor (degrades catecholamines)